<DOC>
	<DOCNO>NCT00316862</DOCNO>
	<brief_summary>This phase II trial study well give cisplatin irinotecan hydrochloride together radiation therapy work treat patient esophageal cancer gastroesophageal junction cancer remove surgery . Drugs use chemotherapy , cisplatin irinotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together radiation therapy surgery may make tumor small reduce amount normal tissue need remove .</brief_summary>
	<brief_title>Cisplatin , Irinotecan , Radiation Therapy Treating Patients With Esophageal Cancer Gastroesophageal Junction Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine pathologic complete response rate patient surgically resectable esophageal cancer treat pre-operatively induction chemotherapy weekly cisplatin irinotecan ( irinotecan hydrochloride ) follow concurrent cisplatin/irinotecan radiation therapy . SECONDARY OBJECTIVES : I . To evaluate potential response progression disease induction chemotherapy positron emission tomography ( PET ) scan . II . To evaluate toxicity tolerability therapy , include surgical morbidity mortality . III . To determine overall survival , disease free survival , pattern failure . OUTLINE : INDUCTION CHEMOTHERAPY ( COURSES 1-2 ) : Patients receive cisplatin intravenously ( IV ) 30 minute irinotecan hydrochloride IV 30-90 minute day 1 8 course 1 2 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . CHEMORADIOTHERAPY ( COURSES 3-4 ) : Beginning 2 week completion induction chemotherapy , patient receive cisplatin irinotecan hydrochloride induction chemotherapy day 1 8 course 3 4 undergo radiotherapy daily 5 day week course 3 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . SURGERY : Approximately 4-8 week completion chemoradiotherapy , patient undergo surgery remove tumor . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma , poorly differentiate carcinoma , carcinoma otherwise specify , esophagus gastroesophageal junction ; biopsy cytology primary tumor , involve regional lymph node , acceptable Tumors must TNM stage T24 , N01 , M0 determine pretreatment endoscopic ultrasound ; T1 tumor eligible T1 , N1 , M0 ; regional thoracic lymph node involvement ( N1 ) permit Disease must clinically limited esophagus gastroesophageal junction ; tumor extend gastroesophageal junction proximal stomach , 50 % tumor must involve distal esophagus gastroesophageal junction ; adenocarcinoma distal esophagus would therefore include tumor distal esophagus , Siewert type I accord Siewert classification , tumor gastroesophageal junction involve equally distal esophagus proximal stomach , Siewert type II ; tumor must surgically resectable No TIS ( insitu carcinoma ) tumor determine T1N0 follow endoscopic ultrasound No clinical involvement endoscopic ultrasound ( EUS ) , compute tomography ( CT ) scan , PET scan supraclavicular celiac lymph node involvement ( stage IVa , T N M1a ) unless prove false positive appropriate biopsy No patient cervical esophageal tumor , gastric cancer minor involvement gastroesophageal junction distal esophagus No patient tracheoesophageal fistulas Patients evidence metastatic disease eligible ; include : Positive malignant cytology pleura , pericardium peritoneum Radiographic evidence distance organ involvement include lung , liver , bone , brain No prior chemotherapy radiotherapy permit ; patient must least 4 week since major surgery , must recover effect minor surgery ( laparoscopy , thoracoscopy ) No prior malignancy ( basal cell/squamous carcinoma skin , insitu cervical carcinoma , superficial transitional cell bladder carcinoma ) permit unless diagnose and/or treat &gt; = 3 year registration without evidence recurrence Eastern Cooperative Oncology Group ( ECOG ) performance status 01 No evidence recurrent laryngeal nerve phrenic nerve paralysis No known Gilbert 's disease No clinically significant hearing loss ; audiogram do patient clinically indicate No history active seizure disorder ; ongoing treatment phenytoin , phenobarbital , antiepileptic medication ; patient receive valproic acid eligible No New York Heart Association class III IV heart disease ; angina myocardial infarction within last 6 month No history clinically significant ventricular arrhythmia require ongoing medication antiarrhythmic Absolute neutrophil count ( ANC ) &gt; = 1,500/ul Platelet count &gt; = 100,000/ul Hemoglobin &gt; = 9 gm/dl Serum creatinine = &lt; upper limit normal ( ULN ) Total serum bilirubin = &lt; 1.5 mg/dl Forced expiratory volume 1 second ( FEV1 ) &gt; = 1.2 liter OR &gt; = 35 % normal value index body size Pulmonary function test ( PFT ) &gt; = 1.2 liter OR &gt; = 35 % normal value index body size</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>